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a  b  s  t  r  a  c  t
The  HPV-16/18  vaccine  (Cervarix®)  is  a  prophylactic  vaccine  for  the  prevention  of  cervical  cancer  and
contains  recombinant  virus-like  particles  (VLPs)  assembled  from  the  L1  major  capsid  proteins  of human
papillomavirus  (HPV)  strains  16  and  18.  Although  a correlate  of protection  has  yet to  be identiﬁed,
HPV-speciﬁc  antibodies  are  thought  to prevent  virus infection  of the  genital  mucosa.  Therefore,  antigen-
speciﬁc  antibodies  as  assessed  by ELISA  or pseudovirion-based  neutralisation  assay  are  frequently
measured  in clinical  trials  to substantiate  the  immune  responses  induced  by  the vaccine.  Measuring
antigen-antibody  binding  avidities,  which  reﬂects  the degree  of afﬁnity  maturation  in  the  B-cells,  is
another  valuable  method  to  assess  the quality  of  the antibody  responses.  Here  we  describe  the  antigen-
speciﬁc  antibody  avidities  in  samples  taken  from  a clinical  trial  examining  the  feasibility  of  adopting
a  two-dose  (Months  0 and  6) schedule  for  9–14 year  olds  instead  of  the  three-dose  schedule  (Months
0,  1 and  6). Antibody  avidity  (i.e.  avidity  index  [AI])  was  determined  in  the ELISA  by the  ratio  of  anti-
body  concentrations  in serum  samples  treated  or  not  with  the  chaotropic  agent  NaSCN.  Importantly,  in
the comparison  between  the  groups  of  two-dose  and  three-dose  recipients,  no differences  in  AIs  were
observed  at Months  7, 24  and  48. The  results  suggest  that from  Month  7  to  48, the  quality  of  the  antibody
response  in  terms  of avidity  was  similar  in the  two-dose  recipients  to that  in  the  three-dose  recipients.
Hence  these  results  support  the adoption  of a two-dose  schedule  in  9–14 year-old  girls.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Oncogenic strains of the human papillomavirus (HPV) cause
ervical cancer [1]; and two particular strains, HPV16 or HPV18,
ave been identiﬁed in over 70% of cervical cancers [2]. The AS04-
djuvanted HPV-16/18 vaccine (Cervarix®; GlaxoSmithKline [GSK]
iologicals SA) is a prophylatic vaccine for the prevention of cer-
ical cancer and contains recombinant virus-like particles (VLPs1)
ssembled from the L1 major capsid proteins of HPV16 and HPV18.
he HPV-16/18 vaccine has demonstrated very high efﬁcacy against
ersistent infections and high-grade lesions associated with HPV-
6/18 as well as cross-protective efﬁcacy against other oncogenic
PV such as HPV31 and 45 [3,4]. Overall, the vaccine efﬁcacy against
ervical intraepithelial neoplasias graded 3 or greater in a cohort of
Abbreviations: VLP, virus-like particle; AI, avidity index; GM,  geometric mean;
MC, geometric mean concentration.
∗ Corresponding author. Tel.: +32 2 656 6206.
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unHPV DNA-negative women has been estimated at 93.2% (95% CI
78.9–98.7), irrespective of HPV type [3].
Since the preferred age range for HPV-16/18 vaccination (9–14
years) is younger than the age range in which efﬁcacy is typically
assessed (beyond 16 years), measurement of the concentration and
quality of antibody responses in this population is crucial [5,6].
Antibodies are thought to play a role in preventing HPV infection
of genital mucosa, even though a correlate of protection has yet to
be identiﬁed [7,8]. Typical methods for assessing antigen-speciﬁc
antibody responses include ELISAs of cervical secretions as well
as serum, pseudovirion-based neutralisation assays, and measur-
ing the frequencies of memory B cells [9–11]. The avidity ELISA
is another measure of the antibody response. Increased antibody
avidity for antigens reﬂects the process of afﬁnity maturation of B
cells in the germinal centres that in the presence of follicular helper
T cells (TFH) progressively produce antibodies with higher afﬁnity
via somatic hypermutation events and develop into B memory cells
or plasma cells [12–14].
Higher avidities of inﬂuenza haemagglutinin (HA1)-speciﬁc
antibodies have been correlated with higher neutralisation titres
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fter a A(H5N1) inﬂuenza vaccination schedule where prime and
oost injections were 12–24 weeks apart [15]. Similarly, higher
ntibody avidities have been associated with higher bactericidal
ctivities in the assessment of Haemophilus inﬂuenzae type b
accines [16,17] and Streptococcus pneumoniae type 6B and 23F
accines [18]. In a recent study of women vaccinated with the
PV-16/18 vaccine, relatively higher levels of HPV16 L1-speciﬁc
ntibodies and avidities were associated with the prevention of
PV31 infection of the cervix [19]. Detailed kinetic measurements
f antigen-speciﬁc antibody avidities have also been made with
he unadjuvanted HPV16-L1 VLP vaccine [20] and the HPV-16/18
accine [10], administered in a three dose schedule (Months 0,
 and 6); and the increase in antibody avidities in these stud-
es are consistent with a process of sequential afﬁnity maturation
21,22].
Although the HPV-16/18 vaccine is licenced in accordance with
 three-dose schedule (Months 0, 1 and 6), a two-dose schedule
s under evaluation in clinical trials (Month 0 and 6 or 12). In one
ecent clinical trial, the feasibility of adopting a two-dose (Month 0
nd 6) schedule for 9–14 year olds has been supported on the basis
f vaccine-speciﬁc antibody responses, as assessed by ELISA and on
he basis of safety during 24 months of follow-up [6]. Furthermore,
wo doses of the vaccine appeared as protective as three doses over
he four years of follow-up, in one clinical trial where some vaccine
ecipients did not complete the three-dose schedule [23].
The aim of this study was to compare the quality of antibody
esponses in clinical trial recipients of two-doses (Months 0 and
 in 9–14 year olds) or three-doses (Months 0, 1 and 6 in 15–25
ear olds) of the HPV-16/18 vaccine by measuring antigen-speciﬁc
ntibody avidities. An initial step in this study was to characterise
 modiﬁed ELISA for measuring avidity using the chaotropic agent
aSCN together with samples taken from other clinical trials of
he HPV-16/18 vaccine using a three-dose (Months 0, 1 and 6)
chedule.
. Materials and methods
.1. Study designs and sample collection
In Studies 1 and 2, serum samples were collected at 1-month
ost-Dose 2 (Month 2) and post-Dose 3 (Month 7) from healthy
emale human subjects who had received three intramuscular
njections (Months 0, 1 and 6) of the HPV-16/18 vaccine from clini-
al trials NCT00196924 (N = 30, 10–14 years old) and NCT00196937
N = 35, 15–28 years old; N = 21, 29–41 years old; and N = 34, 42–55
ears old) [24,25]. In Study 3, serum samples were collected at
, 18, or 42-months post-last dose (Months 7, 24 and 48) from
uman healthy female subjects from clinical trial NCT00541970
ho either had received the HPV-16/18 vaccine as two intramus-
ular injections (Months 0 and 6, N = 30, 9–14 year olds), or three
ntramuscular injections (Months 0, 1 and 6, N = 30, 15–25 year
lds) [6]. The serum samples for the study were randomly selected
rom what was available in the clinical trial archives and with
espect to the trial participants’ identiﬁcation numbers. All serum
amples were stored at −20 ◦C. All trials were approved by research
thics committees of the respective participating countries and
onducted in accordance with the Declaration of Helsinki and
ood Clinical Practice guidelines. Written informed consent was
btained from each trial participant who was at least the age of
onsent. Written informed assent was obtained from each trial par-
icipant below the age of consent in addition to written informed
onsent from her parent/guardian. One Cervarix® dose contains
0 g of HPV16 Ll VLP, 20 g of HPV18 Ll VLP, 50 g 3-O-desacyl-4′-
onophosphoryl lipid A (MPL) and 500 g aluminium hydroxide.
ll doses were constituted in 0.5 ml. (2014) 3232–3236 3233
2.2. Determination of chaotropic agent concentration and avidity
ELISA
Ninety-six well plates were coated with HPV16, HPV18, HPV31
or HPV45 L1 VLPs (0.5 to 1.5 g/ml) overnight at 4 ◦C, and blocked
with 1% bovine serum albumin, 0.1% Tween-20 in phosphate-
buffered saline.
For the determination of the chaotropic agent concentration,
coated wells were incubated with 0–8 M NaSCN for 15 min at room
temperature. After a washing step, wells were incubated with
biotinylated V5 (1.56 ng/ml; anti-HPV16) or J4 (6.25 ng/ml; anti-
HPV18) monoclonal antibodies for 90 min  at 37 ◦C.
For the avidity ELISA, coated wells were incubated with serum
samples (12 serial 2-fold dilutions) for 1 h 30 min at 37 ◦C. After a
washing step, wells were incubated with 0 or 1 M NaSCN for 15 min
at room temperature. After another washing step, wells were then
incubated with biotin-conjugated anti-human IgG (Jackson; Stud-
ies 1 and 2) or Ig (Amersham; Study 3).
Biotinylated antibody detection used the colorimetric readout
based on streptavidin-horseradish peroxidase (Amdex, GE Health-
care) and O-phenylenediamine substrate (Sigma). Optical densities
were read at 492/620 nm and antibody concentrations were calcu-
lated relative to a standard antiserum reference using SoftMaxPro
software (4-parameter equation) and expressed in EU/ml. An avid-
ity index (AI2) was  calculated as a ratio of the antigen-speciﬁc
antibody concentration determined after 1 M NaSCN treatment
divided by the antigen-speciﬁc antibody concentration without
NaSCN treatment.
2.3. Statistics
All statistical analyses were not part of the objectives of the clin-
ical trials from which the samples were taken and therefore were
considered as exploratory. Parametric analyses were performed
using SAS software on log10 transformed data. The Shapiro–Wilk
test, Skewness and Kurtosis calculations were used to conﬁrm nor-
mality. Differences were identiﬁed by ANOVA followed by Tukey’s
test. All comparisons were two-tailed. Pearson’s r statistic was  used
to identify correlations between (log10 transformed) AIs and anti-
body concentrations. Signiﬁcance was  ascribed to p-values <0.05
(and in the case of antibody concentrations, to ≥2-fold differences).
AIs are described to two-signiﬁcant ﬁgures in the text.
3. Results
3.1. Concentration determination of chaotropic agent
The HPV16 L1 and HPV18 L1 conformational epitopes that
are important epitopes for neutralising antibodies [7,26], were
evaluated in an ELISA using monoclonal antibodies V5 and J4,
respectively. Both epitopes were not signiﬁcantly denatured by
15 min  pre-incubation with <4 M NaSCN (Fig. 1). However, 10% of
HPV16 L1 conformational epitopes were denatured by 2 M NaSCN.
Therefore, a 15 min  incubation with 1 M NaSCN in the ELISA was
selected to assess the antibody avidities with serum samples from
HPV-16/18 vaccine recipients.
3.2. Comparisons between AIs at Month 2 and Month 7 in a
three-dose vaccination schedule (Months 0, 1 and 6)
In Study 1 and 2, the AIs of HPV16 L1- and HPV18 L1-speciﬁc
antibodies were assessed in samples taken from vaccinated girls
and women  one month post-Dose 2 (Month 2) and one month post-
Dose 3 (Month 7). In Study 1, samples were taken from 10 to 14
year-old girls, whereas in Study 2, samples were taken from 15 to
55 year-old girls and women  allocated to three groups stratiﬁed
3234 M. Boxus et al. / Vaccine 32
Fig. 1. The selection of 1 M NaSCN as chaotropic agent for the HPV-speciﬁc antibody


































o5 min  incubation of the HPV16 or HPV18 L1 VLPs with different concentrations of
aSCN as measured by the percentage of monoclonal antibodies V5 (black circles)
nd J4 (black triangles) bound in respective ELISA plates.
y age. The AI data from Study 1 and Study 2 were considered in
 single statistical analysis on the assumption that there was no
ffect due to differences between studies.
Because no differences were detected between the HPV16 L1-
peciﬁc and HPV18 L1-speciﬁc AI data sets (p = 0.982), these data
ere considered together in the comparisons between post-Dose 2
nd post-Dose 3. In each age strata and post-Dose 3, the HPV16 L1-
nd HPV18 L1-speciﬁc geometric mean (GM3) AIs ranged from 0.91
o 0.99 (Fig. 2), whereas post-Dose 2, the HPV16 L1- and HPV18 L1-
peciﬁc GM AIs ranged from 0.58 to 0.75 (Fig. 2A). Thus at Month 7
post-Dose 3) compared with Month 2 (post-Dose 2), the increases
n the GM AIs speciﬁc for both HPV L1 antigens ranged from 1.27
o 1.56-fold (p < 0.001) in each age strata. Therefore post-Dose 3,
he proportional enrichments of high-avidity antibodies, speciﬁc
or either of the vaccine antigens, were detectable with these assay
onditions. Moreover, post-Dose 3 compared with post-Dose 2,
he HPV16 L1- and HPV18 L1-speciﬁc antibody geometric mean
oncentrations (GMCs4) of the high avidity antibodies (antibody
oncentrations after NaSCN treatment) increased by 4.0–8.1-fold
nd 3.1–4.0-fold, respectively (p < 0.001; Fig. 2B).The GM AIs speciﬁc for both HPV L1 antigens were not differ-
nt between age strata at Month 7 and post-Dose 3 (p ≥ 0.221;
.94–1.05-fold differences from inter-strata comparisons) even
hough the HPV L1-speciﬁc antibody GMCs of the high avidity
ig. 2. The evaluation of HPV-speciﬁc antibody avidities at Months 2 and 7 with a 0–1–6
eans  (GM; horizontal lines) with 95% conﬁdence intervals (95%CI) of (A) HPV16 L1- and
vidity  antibody concentrations (measured with 1 M NaSCN treatment). Samples were ob
)  in Study 1, and 15–55 year-old girls and women, allocated to three groups stratiﬁed b
N  = 20, post-Dose 2, N = 21, post-Dose 3]; and 42–55 years old [N = 34, post-Dose 2 and 
rey  circles) and one month post-Dose 3 (Month 7, light grey circles). The avidity index (
 M NaSCN over the antibody concentration without NaSCN treatment. Note that in (B)
1-speciﬁc log(AI) versus and respective log(antibody concentration) for individual sampl
f  correlations between AIs and antibody concentrations are described by the Pearson’s r (2014) 3232–3236
antibodies differed by up to 13-fold (Fig. 2B). Therefore, the AIs
at Month 7 appeared unaffected by the age of the vaccine recipient
over a range of 10–55 years. Moreover, no correlations were identi-
ﬁed between HPV16 L1 or HPV18 L1-speciﬁc AIs and the respective
antibody concentrations for individual samples across the four age
strata at Month 7 (Fig. 2C), suggesting that the AI measurement
captures a different aspect of the antibody response to that of the
antibody concentration measured by ELISA without a chaotropic
agent.
3.3. Comparisons between AIs from two-dose (Months 0 and 6)
and three-dose (Months 0, 1 and 6) vaccination schedules
The AIs of HPV16 L1- and HPV18 L1-speciﬁc antibodies and the
non-vaccine strain HPV31 L1- and HPV45 L1-speciﬁc antibodies
were then assessed in samples taken at Months 7, 24 and 48 from
9 to 14 year-old girls who  received two  vaccine doses (Months 0
and 6) and 15 to 25 year-old girls and women who received three
vaccine doses (Months 0, 1 and 6). The two groups were compared,
on the assumption that AIs were unaffected by age of the vaccine
recipient.
At Month 7, 24 or 48, HPV16 L1- or HPV18 L1-speciﬁc GM AIs
were not different between the two-dose group and the three-
dose group (p ≥ 0.385; Fig. 3A). Moreover, from Month 7 to Month
48, HPV16 L1- and HPV18 L1-speciﬁc GM AIs ranged between
0.90–0.94 and 0.85–0.95, respectively, in the two-dose group; and
between 0.88–0.93 and 0.81–0.89, respectively, in the three-dose
group. This suggested that the relative levels of antibodies with
high avidity for vaccine-speciﬁc HPV strains from Month 7 to 48
were similarly induced in the two-dose recipients to those in the
three-dose recipients.
At Month 7, 24 or 48, HPV31 L1- or HPV45 L1-speciﬁc GM AIs
were not different between the two-dose group and the three-
dose group (p ≥ 0.311; Fig. 3B). From Month 7 to Month 48,
HPV31 L1- or HPV45 L1-speciﬁc GM AIs ranged between 0.57–0.60
and 0.56–0.70, respectively, in the two-dose group; and between
0.59–0.61 and 0.54–0.66, respectively, in the three-dose group. This
suggested that the relative levels of antibodies with high avid-
ity for non-vaccine-speciﬁc but related HPV strains were induced
 month HPV-16/18 vaccination schedule. Individual values (circles) and geometric
 HPV18 L1-speciﬁc avidity indices and (B) HPV16 L1- and HPV18 L1-speciﬁc high-
tained from vaccinated 10–14 year-old girls (N = 30, post-Dose 2; N = 29, post-Dose
y age (15–28 years old [N = 35, post-Dose 2, N = 34, post-Dose 3]; 29–41 years old
3]) from Study 2. The samples were taken one month post-Dose 2 (Month 2, dark
AI) was calculated as the ratio of the antibody concentration after treatment with
, a logarithmic scale is used for the y-axis. (C) Scatterplots of HPV16 L1 or HPV18
es from Studies 1 and 2 at Month 7 for the four age strata (N = 117). The evaluations
 coefﬁcients and accompanying p values.
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Fig. 3. The evaluation of HPV-speciﬁc antibody avidities at Months 7, 24 and 48 with
0–6 or 0–1–6 month HPV-16/18 vaccination schedules. Individual values (circles)
and geometric means (GM; horizontal lines) with 95% conﬁdence intervals (95%CI)
of  avidity indices of (A) HPV16 L1- and HPV18 L1-speciﬁc antibodies and (B) the non-
vaccine strain HPV31 L1- and HPV45 L1-speciﬁc antibodies. Samples were obtained
from Study 3, taken at Months 7, 24 and 48 from 9 to 14 year old girls (N = 30, Month
7;  N = 29, Month 24 and 48) who received 2 vaccine doses (Months 0 and 6, dark grey




































m4) who received 3 vaccine doses (Months 0, 1 and 6, light grey circles). The avidity
ndex (AI) was  calculated as the ratio of the antibody concentration after treatment
ith 1 M NaSCN over the antibody concentration without NaSCN treatment.
imilarly at each period examined (Month 7, 24 and 48) in the
wo-dose recipients compared with the three-dose recipients.
. Discussion
This exploratory study supplements the observations made in
he primary analysis of the HPV-16/18 vaccine clinical trial which
emonstrated that the magnitude of antibody responses for the
wo-dose schedule (9–14 year olds) was not inferior to the three-
ose schedule (15–25 year olds) [6]. Hence the limitations of the
resent study are that the analyses were post hoc; and, in the
omparison of the two-dose versus three-dose schedules, it was
ssumed that the age of vaccine recipient had no effect on the mag-
itude of the AI. In the present study, no differences in AIs were
bserved at Months 7, 24 and 48 between the groups of two-dose
nd three-dose HPV-16/18 vaccine recipients, suggesting that the
uality of the antibody responses to HPV16, 18, 31 or 45 L1 VLPs
n terms of avidity was similar in the two groups. As expected, the
Is for HPV31 L1 and HPV45 L1 VLPs were relatively lower than
or HPV16 and 18 L1 VLPs, since these VLPs are not vaccine types
nd the L1 protein sequence homologies with HPV16 and 18 L1 are
3% and 88%, respectively [27]. Therefore, and in line with what
as been proposed with the heptavalent pneumococcal vaccine
28], antibody avidity, in addition to antibody concentration, can
e a useful immunological attribute in the evaluation of alternative
accine schedules.
Antigen-speciﬁc avidity has been assessed in other studies
f HPV vaccines [9,10,19,20,29]. An underlying objective of the
resent study was to use a methodology that can easily be adopted
n the clinical trial setting. Therefore, a single (1 M)  concentra-
ion of the chaotropic agent NaSCN was selected and antibody
oncentrations, with and without chaotropic agent, were calcu-
ated from serum dilution series. Moreover, ELISA-based assays
sing a single concentration of chaotropic agent have been reli-
bly used elsewhere to measure the avidity of polyclonal antibodies
n human serum samples [18,30]. The one-step aspect of the assay
ay  make it more amenable for high-throughput analyses than the (2014) 3232–3236 3235
two-step ELISA methodology reported by Dauner et al. [20,29]. In
that methodology, antibody concentrations were measured in the
ﬁrst ELISA step to calculate the stipulated dilution factors for the
avidity evaluation in the second ELISA step (which used a dilution
series of chaotropic agent). In the present study, the selection of
the 1 M concentration of NaSCN was a conservative choice to avoid
potential artefacts associated with higher concentrations, such as
the modiﬁcation of antigen structural components (e.g. the dis-
ruption of conformational epitopes; or the instability of antigen
attachment to the ELISA plate: see [29] in which Guanidine HCl
and NH4SCN were evaluated).
The relevance of the avidity ELISA in this study was conﬁrmed
by detecting HPV16 and HPV18 L1-speciﬁc AI increases at post-
Dose 3 (Month 7) compared with post-Dose 2 (Month 2). These
increases were in line with a previous study of the same vaccine
[10] and with the anticipated afﬁnity maturation of vaccine-antigen
speciﬁc antibodies [21,22]. The impact of the interval between Dose
1 and Dose 2 in the 2-dose schedule on the magnitude of the AI
was not evaluated. Although the data suggested that HPV16 and
HPV18 L1-specifc AIs were higher one month after Dose 2 in a 0, 6
month schedule than in a 0, 1 month schedule, the length of time
after Dose 1 (seven months rather than two months) may  have also
contributed to the magnitude of the AIs [28].
The absence of strong correlations between AIs and absolute
antibody concentrations concurred with other published observa-
tions, in that the magnitude and quality of the antibody response
are not temporally associated [9–11]. In one of those studies, HPV16
L1-speciﬁc AIs were only correlated with neutralisation responses
at one of the several time points examined over a 36-month post-
vaccination period [10]. Furthermore, although the magnitude of
absolute high-avidity antibody concentrations at Month 7 appeared
to vary with the age of the vaccine recipient, the AI appeared unaf-
fected. Therefore, this suggests that antibody quality (as measured
by AI) is not highly linked to antibody quantity. Instead, the mag-
nitude of the AI may  reﬂect the magnitude of certain aspects of
the T cell response including the involvement of TFH cells in the
clonal selection of B-cell populations, such as B-memory cells and
plasma cells, with high-afﬁnity for the antigens [31]. Moreover, the
induction of persistent B-memory and T cells after immunisation
with HPV-16/18 vaccine has been demonstrated in several stud-
ies [11,32,33]. Hence further investigations could be conducted to
identify the relationship between the avidity of HPV L1-speciﬁc
antibodies, their functional activity and the induction of B-memory
and T cells.
5. Conclusions
In the absence of clinical efﬁcacy data in the 9–14 year olds,
the assessment of the antibody concentration and quality in this
population is crucial. Even if the clinical relevance of the avid-
ity measurements remains to be determined, this study indicates
that AIs from Month 7 to 48 appeared similar for the two-dose
in 9–14 year olds and three-dose HPV-16/18 vaccine schedules in
15–25 year olds. These ﬁndings therefore complement the con-
clusion made in the primary analysis of the clinical trial that
the two-dose schedule was immunologically non-inferior to the
three-dose schedule [6]. This study also supports the use of this
simple modiﬁed ELISA approach to monitor avidities for vac-
cine and non-vaccine speciﬁc antibodies in future HPV vaccine
studies.Funding source
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